What is HC Wainwright’s Estimate for CKPT FY2024 Earnings?

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) – Research analysts at HC Wainwright dropped their FY2024 earnings per share estimates for Checkpoint Therapeutics in a report issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.94) for the year, down from their prior estimate of ($0.80). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Checkpoint Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Checkpoint Therapeutics’ Q4 2024 earnings at ($0.22) EPS.

Checkpoint Therapeutics Price Performance

CKPT stock opened at $3.38 on Monday. Checkpoint Therapeutics has a one year low of $1.36 and a one year high of $3.97. The stock has a market cap of $152.17 million, a price-to-earnings ratio of -1.84 and a beta of 1.23. The company has a fifty day moving average price of $2.87 and a two-hundred day moving average price of $2.38.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08).

Institutional Trading of Checkpoint Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Checkpoint Therapeutics by 67.4% in the 1st quarter. Vanguard Group Inc. now owns 917,894 shares of the company’s stock valued at $1,882,000 after acquiring an additional 369,586 shares during the period. Geode Capital Management LLC increased its stake in shares of Checkpoint Therapeutics by 41.2% during the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock worth $958,000 after purchasing an additional 124,787 shares during the period. B. Riley Wealth Advisors Inc. lifted its holdings in Checkpoint Therapeutics by 366.3% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock worth $493,000 after purchasing an additional 180,050 shares during the last quarter. PVG Asset Management Corp acquired a new stake in Checkpoint Therapeutics during the 2nd quarter worth approximately $295,000. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Checkpoint Therapeutics by 160.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock valued at $291,000 after purchasing an additional 80,000 shares during the period. Institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.